Efficacy of intravenous magnesium in neuropathic pain

被引:75
作者
Brill, S
Sedgwick, PM
Hamann, W
di Vadi, PP
机构
[1] Univ Hosp Lewisham, Dept Anaesthet & Pain Management, London SE13 6LH, England
[2] St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England
[3] Guys & St Thomas Hosp, GKT Sch Med, Pain Management Unit, London SE1 9RT, England
关键词
pain; neuropathic; postherpetic neuralgia;
D O I
10.1093/bja/aef266
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Background. Postherpetic neuralgia is a complication of acute herpes zoster characterized by severe pain and paraesthesia in the skin area affected by the initial infection. There is evidence that the N-methyl-D-aspartate receptor is involved in the development of hypersensitivity states and it is known that magnesium blocks the N-methyl-D-aspartate receptor. Method. A double-blind, placebo-controlled, cross-over study was conducted in which magnesium sulphate was administered as an i.v. infusion. Spontaneous pain was recorded and qualitative sensory testing with cotton wool was performed in seven patients with postherpetic neuralgia before and after the i.v. administration of either magnesium sulphate 30 mg kg(-1) or saline. Results. During the administration, pain scores were significantly lower for magnesium compared with placebo at 20 and 30 min (P=0.016) but not at 10 min. IN. magnesium sulphate was safe, well-tolerated and effective in patients with postherpetic neuralgia. Conclusion. The present study supports the concept that the N-methyl-D-aspartate receptor is involved in the control of postherpetic neuralgia.
引用
收藏
页码:711 / 714
页数:4
相关论文
共 25 条
[1]
Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain [J].
Begon, S ;
Pickering, G ;
Eschalier, A ;
Dubray, C .
BRAIN RESEARCH, 2000, 887 (02) :436-439
[2]
BYASSMITH MG, 1993, 7 WORLD C PAIN, P454
[3]
The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer [J].
Crosby, V ;
Wilcock, A ;
Corcoran, R .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2000, 19 (01) :35-39
[4]
Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks [J].
Demirkaya, S ;
Vural, O ;
Dora, B ;
Topçuoglu, MA .
HEADACHE, 2001, 41 (02) :171-177
[5]
DICKENSON AH, 1994, PROG PAIN RES MANAG, V1, P173
[6]
DULEY L, 1995, LANCET, V345, P1455
[7]
Magnesium: physiology and pharmacology [J].
Fawcett, WJ ;
Haxby, EJ ;
Male, DA .
BRITISH JOURNAL OF ANAESTHESIA, 1999, 83 (02) :302-320
[8]
MAGNESIUM-SULFATE INJECTED SUBCUTANEOUSLY SUPPRESSES AUTOTOMY IN PERIPHERALLY DEAFFERENTED RATS [J].
FERIA, M ;
ABAD, F ;
SANCHEZ, A ;
ABREU, P .
PAIN, 1993, 53 (03) :287-293
[9]
A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches [J].
Ginder, S ;
Oatman, B ;
Pollack, M .
JOURNAL OF EMERGENCY MEDICINE, 2000, 18 (03) :311-315
[10]
SUCCESSFUL TREATMENT OF POSTHERPETIC NEURALGIA WITH ORAL KETAMINE [J].
HOFFMANN, V ;
COPPEJANS, H ;
VERCAUTEREN, M ;
ADRIAENSEN, H .
CLINICAL JOURNAL OF PAIN, 1994, 10 (03) :240-242